Intracoronary Versus Intravenous Abciximab Bolus in Patients With ST-Segment Elevation Myocardial Infarction: 1-Year Results of the Randomized AIDA STEMI Trial

In patients with ST-segment elevation myocardial infarction (STEMI), direct intracoronary as compared with standard intravenous bolus administration of the glycoprotein IIb/IIIa receptor antagonist abciximab acutely causes higher local drug concentrations, greater glycoprotein IIb/IIIa receptor occupancy, and enhanced inhibition of platelet aggregation at the site of thrombus and downstream within the coronary capillary bed . These effects might exert a protective effect on the myocardial microcirculation at the time of reperfusion.

Source: Journal of the American College of Cardiology - July 12, 2013 Category: Cardiology Authors: Steffen Desch, Jochen Wöhrle, Rainer Hambrecht, Harald Rittger, Ralf Birkemeyer, Bernward Lauer, Petra Neuhaus, Oana Brosteanu, Peter Sick, Matthias Pauschinger, Sebastian Kerber, Klaus Kleinertz, Suzanne de Waha, Ingo Eitel, Gerhard Schuler, Holger Thie Tags: Research Correspondence Source Type: research